PPA Intervention
Phase 3Small molecule
PPA Intervention is one of 60 small molecule programs targeting Intracerebral Hemorrhage. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
59
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
119 competitors in Ischemic Stroke
#DrugCompanyPhaseTrials
1Butylphthalide
PPeking Union Medical College Hospital
Phase 3
Tegoprazan
SShandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Phase 3
Aggrastat
MMedicure
Phase 3
Edaravone Dexborneol
SSimcere Pharmaceutical Co., Ltd
Phase 3
SGLT-2 Inhibitors
Novo NordiskPhase 3
PPA Intervention
SSecond Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3
Y-6
BBeijing Tiantan Hospital
Phase 3
Tenecteplase or Alteplase
IInsel Gruppe AG, University Hospital Bern
Phase 3
Proamatine
TakedaPreclinical
Levaquin
WWim Janssens
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Intracerebral Hemorrhage1 trial
Reduction of Edema With a Specialized Cocktail for Ultra-early Management in Intracerebral Hemorrhage
Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 3·NCT06863558·58 enrolled
Ischemic stroke1 trial
Reduction of Edema With a Specialized Cocktail for Ultra-early Management in Ischemic Stroke
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 3·NCT06863571·68 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PPA Intervention. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details